LYRA Stock Overview
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.
Lyra Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.70|
|52 Week High||US$8.18|
|52 Week Low||US$3.30|
|1 Month Change||-22.27%|
|3 Month Change||-36.43%|
|1 Year Change||-32.23%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-80.07%|
Recent News & Updates
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?Dec 14
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business GrowthAug 28
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn RateMay 04
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?Mar 05
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In GrowthJan 11
|LYRA||US Pharmaceuticals||US Market|
Return vs Industry: LYRA underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: LYRA underperformed the US Market which returned -18.5% over the past year.
|LYRA Average Weekly Movement||9.3%|
|Pharmaceuticals Industry Average Movement||10.8%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: LYRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: LYRA's weekly volatility (9%) has been stable over the past year.
About the Company
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps.
Lyra Therapeutics, Inc. Fundamentals Summary
|LYRA fundamental statistics|
Is LYRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LYRA income statement (TTM)|
|Cost of Revenue||US$38.19m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.72|
|Net Profit Margin||-3,367.84%|
How did LYRA perform over the long term?See historical performance and comparison